Fractyl’s Revita hit its six-month goal in a sham-controlled pivotal trial, and the FDA filing is planned for late Q4 2026.

Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.

Twelve abstracts head to The Liver Meeting, including a real-world comparison with resmetirom and four on investigational efruxifermin.

Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.

John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...

Prenuvo and UT Dallas researchers found links between sleep efficiency, visceral fat and brain volume, with long sleepers ...

Steven Austad and Arlan Richardson explore animal longevity, fasting, GLP-1s and biomarkers to reveal what could translate to ...

Bio says its Activin E antibody kept weight loss closer to pure fat in monkeys on semaglutide, and could one day be dosed twice a year.

Fitnescity Health opens its 1,000-plus imaging locations to digital health platforms through one API, with Superpower on ...

United Therapeutics will test treprostinil SMI in about 40 patients with pulmonary hypertension linked to COPD.

The Hanover biomarker company will grow its lab and team to measure protein clumping in Alzheimer’s, Parkinson’s and ALS. Think of a smoke alarm. It goes off when something’s burning and says nothing ...

The Boston company says the deal more than doubles its patient reach and opens a path to brain-based sleep testing in primary care from 2027.